Skip to main content

Select Drug Profiles

ESMO 2020 Highlights
Sotorasib, First-in-Class KRAS G12C Inhibitor, Hailed as “Triumph of Drug Discovery”
Phoebe Starr
Phoebe Starr
Read More
FDA Approvals
Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer
Read More
FDA Approvals
Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma
Read More
FDA Approvals
FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer
Read More
FDA Approvals, Leukemia, Oncology
Oral Onureg First Drug Approved for Adults with AML in Remission
Read More
FDA Approvals
Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow
Read More
FDA Approvals
Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions
Read More
Perspectives
The Dirty Dozen Redux
David B. Nash, MD, MBA
David B. Nash, MD, MBA
Read More
ESMO 2020 Highlights
Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation
Phoebe Starr
Phoebe Starr
Read More
ESMO 2020 Highlights
Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy
Phoebe Starr
Phoebe Starr
Read More
Page 28 of 244
Results 271 - 280 of 2438